Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrekibart PK Study in Healthy Participants
NCT07545590Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2026
- Primary completion
- Sep 2026
- Modality
- IgG Antibodies, PD-1/PD-L1 Inhibitors, Anti-inflammatory mAbs
- Countries
- 1
01
Overview
Phase 1, open-label trial of eltrekibart (4 cohorts), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Observed Drug Concentration, Area Under the Concentration Versus Time Curve From Zero to Infinity and 1 more. Started Apr 2026; status: completed.
02
Drugs
eltrekibart
Beyond the preview
Go deeper on NCT07545590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07545590.